Reena Mehta, MD
Allergy & Immunology · New Orleans, LANPI 1316263858
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,745 of the $158,684 with a category attached, or 79.2%. 33 manufacturers reported payments, led by AstraZeneca at 52.0% of the total. 2025 is the largest year on record at $79,265, more than ten times the $447 reported in 2019. Among allergy & immunology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 576 payments — averaging $275.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$82K
- Sanofi$46K
- Amgen$13K
- Genentech USA, Inc.$12K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$529
- plus $3K from 27 others
What the payments were for
- Consulting fees$5,0493%
- Speaking & faculty fees$125,74579%
- Travel & lodging$14,3459%
- Food & beverage$13,4148%
- Education$1310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 160 | $82,463 |
| Sanofi | 63 | $45,735 |
| Amgen | 16 | $12,837 |
| Genentech USA, Inc. | 43 | $12,207 |
| GSK | 119 | $1,976 |
| Regeneron Healthcare Solutions, Inc. | 28 | $529 |
| Pfizer | 25 | $466 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $407 |
| AbbVie | 13 | $361 |
| Novartis | 13 | $270 |
| Galderma Laboratories, L.p. | 11 | $257 |
| Kaleo, Inc. | 9 | $146 |
| Aimmune Therapeutics, Inc. | 5 | $130 |
| Grifols USA, LLC | 5 | $115 |
| Alk-abello, Inc | 6 | $96 |
| CSL Behring | 6 | $90 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $68 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Biocryst US Sales Co., LLC | 2 | $43 |
| LEO Pharma Inc. | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Phadia US Inc. | 2 | $35 |
| ADMA Biomanufacturing LLC | 2 | $34 |
| Optinose US, Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Incyte Corporation | 2 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $26 |
| Organon | 3 | $23 |
| Blueprint Medicines Corporation | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$158,684 in reported general payments places this provider in the 95th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 82 | $317,935 |
| TezspireTezepelumab-Ekko | 45 | $231,452 |
| Dupixent SyringeDupilumab | 48 | $189,071 |
| XolairOmalizumab | 59 | $164,296 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 18 | $112,752 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $92,103 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $68,986 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,629 |
| Epinephrine | 24 | $3,790 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,050 |
| Azelastine Hcl | 53 | $2,140 |
| Fluticasone Propionate | 33 | $661 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $618 |
| Hydroxyzine Hcl | 24 | $464 |
| Famotidine | 32 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere | $82,463 | $240,08056 claims |
| GSKTrelegy Ellipta | $1,976 | $92,103129 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $407 | $68,98636 claims |
| Hikma Pharmaceuticals USAEpinephrine | $38 | $3,79024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in New Orleans
- Kenneth ParisNew Orleans$150K
- Cheryl WilliamsNew Orleans$12K
- Luke WallNew Orleans$7K
- Stephen DerbesNew Orleans$2K
- Michelle Korah-SedgwickNew Orleans$2K
- Jamie LurieNew Orleans$2K
- William DavisNew Orleans$2K
- Elizabeth WisnerNew Orleans$2K
- Dexter MatranaNew Orleans$1K
- Meaghan McMahonNew Orleans$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.